Familial Hypercholesterolemia
10.12376/j.issn.2097-0501.2023.01.002
- VernacularTitle:家族性高胆固醇血症
- Author:
Siqin FENG
1
,
2
,
3
;
Muyun TANG
1
,
2
,
3
;
Wei WU
1
,
2
,
3
;
Shuyang ZHANG
1
,
2
,
3
Author Information
1. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &
2. Peking Union Medical College, Beijing 100730, China.State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &
3. Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
familial hypercholesterolemia;
low-density lipoprotein cholesterol;
proprotein convertase subtilisin/kexin type 9 inhibitors
- From:
JOURNAL OF RARE DISEASES
2023;2(1):6-16
- CountryChina
- Language:Chinese
-
Abstract:
Familial hypercholesterolemia (FH) is a group of autosomal co-dominant genetic diseases mainly characterized by abnormal low-density lipoprotein related metabolism. It is one of the most common inherited diseases in children and one of the most serious lipid metabolism diseases which results in various life-threatening cardiovascular diseases and the complications. In recent years, the treatment protocols for FH have diversified thanks to the deeper understanding of the disease in China and abroad and the development of new lipid-lowering drugs. However, the current awareness and diagnosis rate of FH are very low. The treatment of the disease is much inadequate. This paper summarizes the clinical characteristics, diagnosis, screening strategy, and treatment of FH hoping to enhance the understanding and awareness of the disease in the society.
